Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
CORRECTED - A proposal to reduce the Term of Office for Board Members to one
year was rejected rpt rejected. An earlier release incorrectly reported this
vote. Follows hereafter the corrected version
ALLSCHWIL/BASEL, SWITZERLAND - 05 May 2011 - At today's Annual General Meeting
of Actelion Ltd (SIX: ATLN) held in Basel Switzerland, shareholders voted on a
number of resolutions put forward by the Company's Board and a Requesting
Shareholder.
The meeting was attended by 486 shareholders, representing 78'430'215 shares or
60.41 % of the total outstanding shares.
Shareholders approved the Business Report, consisting of the Annual Report, the
Annual Statutory Accounts and the Consolidated Accounts for the year 2010.
A proposal by the Board to appropriate available earnings from capital
contribution and distribute as a dividend in the amount of CHF 0.80 per
registered share, was passed by shareholders.
A request for information from a shareholder was addressed by the Board of
Directors and a further request for a special audit "Sonderprüfung" was
rejected.
Shareholders granted discharge to all members of the Board of Directors and of
the Senior Management.
A proposal by the Board to approve the continuation of a share repurchase
program, of up to CHF 800 million, which commenced in November 2010, was passed
by shareholders.
Shareholders voted on a number of resolutions to amend Actelion's Articles of
Association as follows:
* A proposal to introduce a consultative vote on the Compensation Report was
approved.
* A proposal regarding the implementation of the Book Entry Securities Act was
approved.
* A proposal to remove the maximum limit in number of Board Members was
rejected.
* A proposal to reduce the Term of Office for Board Members to one year was
rejected.
* A proposal that Shareholders should elect the Chairman of the Board at the
AGM was rejected.
Shareholders voted against a proposal from the Requesting Shareholder to remove
five members of the current Board.
Actelion's shareholders voted to re-elect Dr. Jean-Paul Clozel, Mr. Juhani
Anttila, and Mr. Carl Feldbaum to the Board for a term of one year.
Shareholders also voted to elect two new Directors, Dr. Jean-Pierre Garnier and
Mr. Robert Bertolini to the Board for a term of one year.
Following the AGM, Actelion's Board comprises a total of eleven members: Robert
E. Cawthorn (Chairman), Jean-Pierre Garnier (Vice-Chairman), Joseph C. Scodari
(Vice-Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, Carl
Feldbaum, Werner Henrich, Michael Jacobi, Armin Kessler, and Jean Malo.
Finally, shareholders confirmed Ernst & Young as the Company's statutory
auditors for the year 2011.
###
Notes to the Editor
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1512912/448608.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1512912]
Unternehmensinformation / Kurzprofil:
Datum: 05.05.2011 - 15:15 Uhr
Sprache: Deutsch
News-ID 54308
Anzahl Zeichen: 5746
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
